Navigation Links
FDA Approves PREZISTA®/ritonavir Once-Daily Dosing for HIV-1 Treatment-Experienced Adults With No Darunavir Resistance-Associated Mutations
Date:12/13/2010

ild to moderate, regardless of causality) occurred in 10.3% of patients receiving PREZISTA/ritonavir. Discontinuation due to rash was 0.5%


  • Sulfa Allergy: PREZISTA should be used with caution in patients with known sulfonamide allergy

  • Diabetes Mellitus/Hyperglycemia and Hemophilia: New-onset or exacerbations of preexisting diabetes mellitus, hyperglycemia, and increased bleeding in hemophiliacs have been reported in patients receiving protease inhibitors. Initiation or dose adjustments of insulin or oral hypoglycemic agents may be required. A causal relationship between protease inhibitors and these events has not been established

  • Fat Redistribution: Redistribution and/or accumulation of body fat have been observed in patients receiving ARV therapy. The causal relationship, mechanism, and long-term consequences of these events have not been established

  • Immune reconstitution syndrome has been reported in patients treated with ARV therapy

  • Resistance/Cross Resistance: The potential for HIV-1 cross-resistance among protease inhibitors has not been fully explored in PREZISTA/ritonavir-treated patients

  • Use in Specific Populations

  • Hepatic Impairment: PREZISTA/ritonavir is not recommended for use in patients with severe hepatic impairment. There are no pharmacokinetic or safety data available in patients with severe hepatic impairment

  • Pregnancy: PREZISTA should be used during pregnancy only if the potential benefit justifies the potential risk. No adequate and well-controlled studies have been conducted in pregnant women

  • Adverse Reactions

  • In treatment-naïve adult patients, the most common adverse drug reactions (greater than or equal to 5%) reported of at least
    '/>"/>

  • SOURCE Tibotec Therapeutics
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
    2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
    3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
    4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
    5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
    6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
    7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
    8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
    9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
    10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
    11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)...   Synageva BioPharma Corp. (NASDAQ: ... products for rare disorders, today announced validation by ... Authorization Application (MAA) for sebelipase alfa for LAL ... for accelerated assessment, which has the potential to ... The MAA, and the Biologics License Application ...
    (Date:12/24/2014)... , Dec. 23, 2014  Lockton Dunning ... of Lockton Companies, announced the addition of Vice ... will join Lockton Dunning,s Pharmacy Consulting team, Excelsior ... of relevant industry experience to the position.  Most ... Market Sales at Diplomat Specialty Pharmacy, where she ...
    (Date:12/24/2014)... , Dec. 23, 2014 Tianyin Pharmaceutical ... that specializes in patented biopharmaceutical, modernized traditional Chinese ... (API) today announced that the Company achieved the ... Manufacturing Practice (GMP) certificate of TPI,s Qionglai Facility ... (CFDA). The public notice period is a significant ...
    Breaking Medicine Technology:Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3Kim Foerster Joins Lockton Companies 2TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3
    ... Oct. 27 According to Millennium Research Group ... intelligence, the European arthroscope market generated over $30 ... over 2009 due to decreasing scope prices and ... Due to unfavorable economic conditions, manufacturers are ...
    ... today announced that it has received approval from the ... (US 7,815,929) regarding a method for the preparation, storage ... very nature, the process of compounding suppositories is cumbersome, ... Indu Muni, founder, chairman, and CEO of CutisPharma, Inc. ...
    Cached Medicine Technology:Despite Rising Procedure Volumes, the $30 Million European Arthroscope Market Experienced Nominal Growth in 2010 2Despite Rising Procedure Volumes, the $30 Million European Arthroscope Market Experienced Nominal Growth in 2010 3CutisPharma Announces Issuance of an Additional Patent for Suppository Compounding 2
    (Date:12/25/2014)... (PRWEB) December 26, 2014 The ... CAGR of 7.2% to reach $5,756.0 million by ... the microscopy market. The electron microscopes product segment ... the forecast period. , Rising focus on nanotechnology, ... growth of the microscopy market. , Get Full ...
    (Date:12/25/2014)... (PRWEB) December 26, 2014 The report ... 2023” focuses on the current treatment landscape, unmet needs, ... market. TS-1 is an anti-cancer drug which is typically ... and is also used for treating gastric cancer and ... otastat potassium. The drug was first approved in 1999 ...
    (Date:12/25/2014)... Recently, Dylan Queen, a famous online company ... collection of discounted prom dresses, most of which are ... of the company, the promotion is valid until Jan. ... expand the UK market. , The prom dresses in ... and styles: A-line strapless, empire strapless chiffon, one shoulder, ...
    (Date:12/25/2014)... December 25, 2014 Helen Harris’ RP ... Woodland Hills, California after an 8 year battle with ... Christmas Eve evening in her home in Woodland Hills ... breast cancer. , As the founder ... years, she pioneered and championed many of today's greatest ...
    (Date:12/25/2014)... -- The risk of burns from fires and cooking ... be extra cautious, an expert says. "Between Thanksgiving ... in patients coming in with burns," said Dr. Steven ... Burn Center of Stony Brook University Hospital in New ... but if not careful, could quickly turn tragic," Sandoval ...
    Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:Don't Let Burns Mar Your Holidays 2
    ... anesthetics are most commonly used for cosmetic procedures and to ... as lidocaine, tetracaine, benzocaine, and prilocaine in a cream, ointment, ... products can cause serious and life-threatening side effects such as ... stop breathing. ,According to the FDA the ...
    ... condition called nephrogenic systemic fibrosis (NSF)— which occurs only ... use of gadolinium dyes for MRI scans, reports a ... Society of Nephrology. ,An accompanying editorial identifies ... be avoided, at least until more information is available. ...
    ... in two cases, greater than $100,000 -- by people without ... a class of drugs commonly used to treat the neurological ... is the first to describe this compulsive gambling in RLS ... receptors in the brain. ,The extent of this ...
    ... relying on beauticians and barbers to spread awareness of ... ,What they can do may be as vital as ... slated for presentation this week at the American Stroke ... ideal place to educate minority women about strokes. ...
    ... decided to appoint ayurveda, homeopathy and unani doctors without ... interview. ,Clearing the way for the ... decided that the government would advertise for the posts ... ,The interviews would be held at the division level. ...
    ... beneficial, standardized recommendations for public health.// ... Mayer USDA Human Nutrition Research on Aging (USDA ... Supplements and Chronic Disease Prevention,” outlines challenges and ... and minerals. ,"The evidence regarding vitamin ...
    Cached Medicine News:Health News:FDA Warns of Deadly Results of Skin-numbing Creams 2Health News:MRI Contrast Agent Linked to Complication in Renal Patients 2Health News:Medications for Restless Legs Syndrome may Trigger Compulsive Gambling 2Health News:Medications for Restless Legs Syndrome may Trigger Compulsive Gambling 3Health News:Beauticians and Barbers can Do More Than Their Services 2Health News:Effective Marketing of Multivitamins Essential 2
    High temp cauteries, fine tip micro....
    Thru cut kerrison style punch 30 deg, 2.75 X 1.4 mm cut, 110 working length....
    6 mm, 45 degree upwards, detachable....
    Aaron 2250 is a multipurpose electrosurgical generator with monoploar and bi-polar functions....
    Medicine Products: